PL324091A1 - Compositions and procedure for treating sclerosis multiplex - Google Patents

Compositions and procedure for treating sclerosis multiplex

Info

Publication number
PL324091A1
PL324091A1 PL95324091A PL32409195A PL324091A1 PL 324091 A1 PL324091 A1 PL 324091A1 PL 95324091 A PL95324091 A PL 95324091A PL 32409195 A PL32409195 A PL 32409195A PL 324091 A1 PL324091 A1 PL 324091A1
Authority
PL
Poland
Prior art keywords
compositions
procedure
sclerosis multiplex
treating sclerosis
treating
Prior art date
Application number
PL95324091A
Other languages
English (en)
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of PL324091A1 publication Critical patent/PL324091A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rehabilitation Therapy (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL95324091A 1994-10-25 1995-10-25 Compositions and procedure for treating sclerosis multiplex PL324091A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15

Publications (1)

Publication Number Publication Date
PL324091A1 true PL324091A1 (en) 1998-05-11

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95324091A PL324091A1 (en) 1994-10-25 1995-10-25 Compositions and procedure for treating sclerosis multiplex

Country Status (15)

Country Link
EP (1) EP0787147A1 (is)
JP (1) JPH10504039A (is)
AU (1) AU4278296A (is)
BR (1) BR9509438A (is)
CA (1) CA2203629A1 (is)
CZ (1) CZ122697A3 (is)
FI (1) FI971750A7 (is)
HU (1) HUT77047A (is)
IL (1) IL115766A0 (is)
IS (1) IS4466A (is)
NO (1) NO971900L (is)
PL (1) PL324091A1 (is)
SI (1) SI9520118A (is)
SK (1) SK51297A3 (is)
WO (1) WO1996012737A2 (is)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US6737406B1 (en) 1996-03-21 2004-05-18 Circassia, Ltd. Cryptic peptides and method for their identification
WO1998006861A2 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2201841C (en) * 1997-04-04 2010-01-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
CN1308671A (zh) * 1998-05-05 2001-08-15 科里克萨公司 髓磷脂碱性蛋白肽及其应用
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
AU2003219432B2 (en) 2002-03-27 2010-04-01 Pharmascience Inc. Antisense IAP nucleobase oligomers and uses thereof
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
EP2091568A2 (en) 2006-10-31 2009-08-26 East Carolina University Fusion proteins comprising a anti-inflammatory cytokine and an antigen for treatment of immune disorders
WO2010024927A2 (en) * 2008-08-28 2010-03-04 The Research Foundation Of State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
CA2757287C (en) * 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
EP2488196B1 (en) 2009-10-12 2015-12-16 LIFEBio Laboratories LLC Composition for treatment of multiple sclerosis
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
BR112013023978B1 (pt) 2011-03-21 2021-09-08 Atlantic Cancer Research Institute Polipeptídeo com afinidade por proteínas de choque térmico e seu uso em diagnóstico de doença infecciosa, produção de resposta imune e tratamento de câncer, bem como ácido nucleico, composição e método de fracionamento de substância para pesquisa ou análise clínica de amostra biológica
AU2015204452A1 (en) 2014-01-13 2016-08-11 Berg Llc Enolase 1 (Eno1) compositions and uses thereof
EP4212547A1 (en) 2015-12-03 2023-07-19 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359783B2 (en) * 1987-06-24 2002-04-17 Autoimmune, Inc. Treatment of autoimmune diseases by oral administration of autoantigens
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
CA2070281C (en) * 1989-12-20 2005-08-23 David Allen Hafler Improved treatment of autoimmune diseases by aerosol administration of auto antigens
AU651097B2 (en) * 1990-03-02 1994-07-14 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
AU3220693A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
HU220357B (hu) * 1992-02-28 2001-12-28 Autoimmune Inc. Eljárás és készítmények autoimmun betegségek kezelésére bystander antigén alkalmazásával
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
CA2133749A1 (en) * 1992-04-09 1993-10-28 Howard L. Weiner Suppression of t-cell proliferation using peptide fragments of myelin basic protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
AU5080393A (en) * 1992-08-17 1994-03-15 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
KR960705038A (ko) * 1993-09-03 1996-10-09 스테시 엘. 채닝 자기 면역 질환에 관련된 프로토콜에서 미엘린 올리고덴드로시트 당 단백질 및 그의 펩타이드 부분들의 용도(users of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune desease)
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
EP0720622A1 (en) * 1993-09-22 1996-07-10 The Board Of Trustees Of The Leland Stanford Junior University Interaction of t-cell receptors and antigen in autoimmune disease
WO1995027499A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or type i interferon
AU695883B2 (en) * 1994-04-08 1998-08-27 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or Th2-enhancing cytokines
HUT76099A (en) * 1994-05-10 1997-06-30 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
AU696637B2 (en) * 1994-06-09 1998-09-17 Delta-Crystallon B.V. Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
EP1172376A1 (en) * 1994-11-18 2002-01-16 Neurocrine Biosciences, Inc. Peptide analogues at position 91 of human myelin basic protein for treatment of multiple sclerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

Also Published As

Publication number Publication date
WO1996012737A3 (en) 1996-10-10
NO971900D0 (no) 1997-04-24
HUT77047A (hu) 1998-03-02
IS4466A (is) 1997-04-17
FI971750A7 (fi) 1997-06-24
BR9509438A (pt) 1997-12-23
SK51297A3 (en) 1998-03-04
FI971750A0 (fi) 1997-04-24
AU4278296A (en) 1996-05-15
EP0787147A1 (en) 1997-08-06
WO1996012737A2 (en) 1996-05-02
JPH10504039A (ja) 1998-04-14
NO971900L (no) 1997-06-25
SI9520118A (sl) 1998-08-31
IL115766A0 (en) 1996-01-19
CA2203629A1 (en) 1996-05-02
CZ122697A3 (en) 1997-09-17

Similar Documents

Publication Publication Date Title
PL324091A1 (en) Compositions and procedure for treating sclerosis multiplex
GB9422571D0 (en) Haemorrihoidal compositions and method of use
IL129138A0 (en) Methods and compositions for immunomodulation
IL127446A (en) Compositions and methods for coating medical devices
EP0874828A4 (en) PAIN TREATMENT COMPOSITIONS
EP0904345A4 (en) DISINFECTANT COMPOSITIONS AND METHODS FOR DISINFECTING SURFACES
GB9415421D0 (en) Cosmetic compositions and processes for manufacture thereof
PL317197A1 (en) Compositions for and method of treating sclerosis multiplex
GB9624501D0 (en) Insecticial compositions and method
GB9405229D0 (en) Compositions of matter
IL111554A (en) Methods and compositions for hair treatment
GB9415420D0 (en) Cosmetic compositions and processes for manufacture thereof
IL112564A0 (en) 1-beta-methyl-carbapenems and compositions containing them
HU9701150D0 (en) Composition for preventing and treating disturbances of vision
IL124419A0 (en) Composition for treating pain
GB9508546D0 (en) Method and composition
PL314588A1 (en) Application of pentoxyphyline in treatment of sclerosis multiplex
GB9419087D0 (en) Method and composition
GB9414888D0 (en) Method and composition
IL113444A0 (en) Compositions and methods for treating leukemia
GB9416340D0 (en) Oil treatment and compositions therefor
ZA953730B (en) Compositions and treatment for multiple sclerosis
ZA959033B (en) Composition and treatment for multiple sclerosis
GB9602269D0 (en) Novel compounds and methods for treating multiple sclerosis
ZA955409B (en) Keratolytic-wound healing compositions and methods for preparing and using same